Idexx Laboratories (IDXX) Current Deferred Revenue (2009 - 2026)

Idexx Laboratories has reported Current Deferred Revenue for 18 years, with the latest figure at $36.4 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue changed 0.21% year-over-year to $36.4 million in Q2 2026; TTM through Jun 2026 was $36.4 million, a 0.21% change from a year earlier, with the FY2025 full-year figure at $35.3 million, up 4.33% from the prior year.
• Current Deferred Revenue was $36.4 million for Q2 2026 at Idexx Laboratories, roughly flat from $36.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $40.9 million in Q1 2022, with the low at $33.8 million in Q4 2024.
• Average Current Deferred Revenue over 5 years is $37.4 million, with a median of $37.5 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue fell 9.13% in 2024, then advanced 4.33% in 2025.
• Over 5 years, Current Deferred Revenue stood at $37.9 million in 2022, then retreated by 1.96% to $37.2 million in 2023, then retreated by 9.13% to $33.8 million in 2024, then advanced by 4.33% to $35.3 million in 2025, then rose by 3.22% to $36.4 million in 2026.
• The last three Current Deferred Revenue figures came in at $36.4 million (Q2 2026), $36.3 million (Q1 2026), and $35.3 million (Q4 2025), per Business Quant data.